Efzofitimod for the Treatment of Pulmonary Sarcoidosis

BACKGROUND: Pulmonary sarcoidosis is characterized by the accumulation of immune cells that form granulomas affecting the lungs. Efzofitimod (ATYR1923), a novel immunomodulator, selectively binds neuropilin 2, which is upregulated on immune cells in response to lung inflammation. RESEARCH QUESTION:...

Descripción completa

Detalles Bibliográficos
Autores principales: Culver, Daniel A., Aryal, Shambhu, Barney, Joseph, Hsia, Connie C.W., James, W. Ennis, Maier, Lisa A., Marts, Lucian T., Obi, Ogugua Ndili, Sporn, Peter H.S., Sweiss, Nadera J., Shukla, Sanjay, Kinnersley, Nelson, Walker, Gennyne, Baughman, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2023
Materias:
Diffuse Lung Disease: Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258437/
https://www.ncbi.nlm.nih.gov/pubmed/36356657
http://dx.doi.org/10.1016/j.chest.2022.10.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258437/
https://www.ncbi.nlm.nih.gov/pubmed/36356657
http://dx.doi.org/10.1016/j.chest.2022.10.037

Ejemplares similares